Cervical cancer screening is entering a recent era, with updated guidelines from two key organizations – the American Cancer Society (ACS) and the Health Resources and Services Administration (HRSA) – now endorsing the use of HPV primary testing and, significantly, self-collected HPV tests. These changes, announced at the end of 2025 and in January 2026 respectively, aim to broaden access to potentially life-saving screenings, particularly for individuals who face barriers to traditional methods. Human papillomavirus (HPV) is a major cause of cervical cancer, and these updated guidelines reflect advances in understanding and testing for the virus.
For decades, cervical cancer screening primarily relied on the Pap test, which looks for precancerous changes in cervical cells. More recently, HPV testing – which identifies the presence of high-risk HPV types – has become increasingly common. Now, both the ACS and HRSA recommend that, for individuals aged 30 to 65, HPV primary testing should be the preferred method. This approach directly identifies the virus responsible for most cervical cancers, offering a more accurate assessment of risk. If HPV primary testing isn’t available, co-testing – combining an HPV test with a Pap test – is recommended. If neither is available, a Pap test alone remains an option.
Expanding Access with Self-Collection
Perhaps the most significant shift in these new guidelines is the acceptance of self-collected HPV tests. Traditionally, samples for both Pap and HPV tests have been collected by a healthcare provider during a pelvic exam. While provider collection remains the preferred method according to the ACS, the guidelines acknowledge that this can be challenging or uncomfortable for some. “Self-collected HPV tests are an acceptable alternative,” the ACS states, recognizing the necessitate to remove barriers to screening. HRSA also explicitly calls for screening with self-collection to be acceptable. This means individuals can collect their own samples, potentially at home, a primary care provider’s office, an urgent care clinic, or even some pharmacies.
This change is particularly impactful for those who lack access to gynecological care, perceive uncomfortable with pelvic exams, or live in areas with limited healthcare resources. The ability to self-collect a sample could dramatically increase screening rates among underserved populations. Information about self-collection tests is available to help individuals understand the process and ensure accurate results.
Navigating Screening Intervals and Age Recommendations
The frequency of screening depends on the type of test used and how the sample was collected. Individuals who receive HPV primary testing or co-testing with a provider-collected sample and have normal results should be screened again in five years. However, the ACS specifies that those who self-collect their HPV samples and receive normal results should be screened again in three years – a distinction not included in the HRSA guidelines. Those who only receive a Pap test and have normal results should be screened every three years. Anyone with abnormal results will require more frequent monitoring.
There’s also some divergence in recommended starting ages for screening. The ACS suggests beginning screening at age 25, citing that cervical cancer is rare in younger individuals. HRSA, however, recommends Pap tests every three years starting at age 21, with a transition to HPV primary testing or co-testing at age 30.
What This Means for Patients and Insurance Coverage
For most patients, the specific screening test offered will depend on their healthcare provider’s practice. With both organizations prioritizing HPV primary testing, it’s likely that more providers will adopt this method in the coming years. The shift towards HPV primary testing is expected to improve the accuracy of screening and reduce the number of unnecessary colposcopies – follow-up procedures to investigate abnormal Pap test results.
The HRSA guidelines carry significant weight with insurance companies. Most private insurance plans are required to cover all recommended testing options, including follow-up care, without copays, starting with policies renewed in 2027. This means that individuals will have greater access to affordable and comprehensive cervical cancer screening.
The ultimate goal of these updated guidelines is to prevent more cases of cervical cancer. Regular screening remains the most effective way to detect precancerous changes and ensure timely treatment. Anyone with questions about their individual screening needs should consult with a healthcare provider.
Disclaimer: This article provides general information about cervical cancer screening guidelines and should not be considered medical advice. Always consult with a qualified healthcare professional for personalized recommendations and treatment options.
The implementation of these new guidelines will continue to unfold in the coming months, and years. Healthcare providers will need to update their practices, and insurance companies will need to adjust their coverage policies. The next key checkpoint will be monitoring the impact of these changes on screening rates and cervical cancer incidence, with data expected to become available in late 2027 and early 2028.
Have questions about the new HPV screening guidelines? Share your thoughts in the comments below, and please share this article with anyone who might find it helpful.
